MA51733A - Composition contraceptive présentant des effets cardiovasculaires réduits - Google Patents

Composition contraceptive présentant des effets cardiovasculaires réduits

Info

Publication number
MA51733A
MA51733A MA051733A MA51733A MA51733A MA 51733 A MA51733 A MA 51733A MA 051733 A MA051733 A MA 051733A MA 51733 A MA51733 A MA 51733A MA 51733 A MA51733 A MA 51733A
Authority
MA
Morocco
Prior art keywords
cardiovascular effects
contraceptive composition
reduced cardiovascular
reduced
contraceptive
Prior art date
Application number
MA051733A
Other languages
English (en)
Inventor
Maud Jost
Glwadys Rausin
Original Assignee
Estetra Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estetra Sprl filed Critical Estetra Sprl
Publication of MA51733A publication Critical patent/MA51733A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA051733A 2018-02-07 2019-02-07 Composition contraceptive présentant des effets cardiovasculaires réduits MA51733A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18155571 2018-02-07
EP18160586 2018-03-07

Publications (1)

Publication Number Publication Date
MA51733A true MA51733A (fr) 2020-12-16

Family

ID=65278388

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051733A MA51733A (fr) 2018-02-07 2019-02-07 Composition contraceptive présentant des effets cardiovasculaires réduits

Country Status (17)

Country Link
EP (2) EP3749327A1 (fr)
JP (2) JP2021513507A (fr)
CN (2) CN115429806A (fr)
AU (1) AU2019219070A1 (fr)
CA (2) CA3089804A1 (fr)
CL (1) CL2020002017A1 (fr)
EC (1) ECSP20054822A (fr)
GE (1) GEP20227407B (fr)
IL (1) IL276584B2 (fr)
JO (1) JOP20200169A1 (fr)
MA (1) MA51733A (fr)
PH (1) PH12020500601A1 (fr)
SG (1) SG11202007163WA (fr)
TW (1) TWI845496B (fr)
UA (1) UA126746C2 (fr)
UY (1) UY38075A (fr)
WO (1) WO2019154899A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2988485A1 (fr) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Comprime orodispersible contenant de l'estetrol
SI3310333T1 (sl) 2015-06-18 2020-08-31 Estetra Sprl Orodisperzibilna enota odmerka, ki vsebuje komponento estetrola
EP3310346B1 (fr) 2015-06-18 2021-03-24 Estetra SPRL Comprimé orodispersible comprenant estetrol
KR102664563B1 (ko) 2015-06-18 2024-05-09 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 에스테트롤 성분을 함유하는 구강분해성 투여 단위
CA3178291A1 (fr) 2016-08-05 2018-04-12 Estetra Srl Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
TW202203935A (zh) * 2020-04-16 2022-02-01 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
WO2022248733A1 (fr) 2021-05-28 2022-12-01 Neuralis Sa Utilisation d'estétrol dans le traitement de maladies infectieuses respiratoires

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
DK1390042T3 (da) * 2001-05-23 2008-03-31 Pantarhei Bioscience Bv System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse
EP1535618A1 (fr) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Préparation pharmaceutique pour le traitement hormonal continuel sur plus de 21-28 jours comprenant deux compositions d'estrogène et/ou de progestine
CN102438628A (zh) * 2009-05-22 2012-05-02 拜耳医药股份有限公司 包含至少一种雌激素和/或至少一种孕激素和至少一种益生菌菌株的供口服给药的药物
WO2012055840A1 (fr) * 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition et préparation pour le traitement de la dysménorrhée et de la douleur menstruelle et utilisation d'un agent hormonal et d'un sel de zinc pour le traitement de troubles menstruels
CN105979935B (zh) * 2013-12-12 2019-07-26 多内斯塔生物科学股份有限公司 包含雌四醇组分的口崩固体剂量单位
JP2018533542A (ja) 2016-10-28 2018-11-15 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ 月経困難症および月経痛の管理のための方法
CA3178291A1 (fr) * 2016-08-05 2018-04-12 Estetra Srl Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles

Also Published As

Publication number Publication date
CL2020002017A1 (es) 2020-12-04
TWI845496B (zh) 2024-06-21
CA3089804A1 (fr) 2019-08-15
EP3749327A1 (fr) 2020-12-16
IL276584A (en) 2020-09-30
WO2019154899A1 (fr) 2019-08-15
KR20200118464A (ko) 2020-10-15
JOP20200169A1 (ar) 2020-07-07
JP2021513507A (ja) 2021-05-27
ECSP20054822A (es) 2020-12-31
UA126746C2 (uk) 2023-01-18
CN115429806A (zh) 2022-12-06
CN111683664A (zh) 2020-09-18
SG11202007163WA (en) 2020-08-28
JP2024009834A (ja) 2024-01-23
IL276584B1 (en) 2024-06-01
CA3178181A1 (fr) 2019-08-15
PH12020500601A1 (en) 2021-05-17
EP4140489A1 (fr) 2023-03-01
IL276584B2 (en) 2024-10-01
GEP20227407B (en) 2022-08-25
TW202011967A (zh) 2020-04-01
UY38075A (es) 2019-10-01
AU2019219070A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
MA51733A (fr) Composition contraceptive présentant des effets cardiovasculaires réduits
HK1257183B (zh) 半氟化化合物和其組合物
DK3697376T3 (da) Sammensætning
DK3394248T3 (da) Dendritisk cellesammensætning
IL262390A (en) Semaglutide in cardiovascular conditions
DK3528902T3 (da) Ringegelsammensætning
IL259183B (en) Food supplement and preparation for the treatment of metabolic syndrome
ITUA20162751A1 (it) Composizione secca in polvere
DK3459354T3 (da) Glyceridsammensætning
FI20160183L (fi) Parannettu puolijohdekokoonpano
DK3423082T3 (da) Liraglutid ved kardiovaskulære tilstande
DK3416502T3 (da) Glykæmisk-reducerende sammensætning
ES1209313Y (es) Composicion liofilizada
IT201600111393A1 (it) Composizione antifungina
DK3359185T3 (da) Antitumoral sammensætning
DK3576546T3 (da) Probiotisk sammensætning
DK3470482T3 (da) Coatingsammensætning
IT201700078091A1 (it) Nuove composizioni antifungine
FR3050907B1 (fr) Composition pour complement alimentaire
JP2017014187A5 (fr)
GB201707700D0 (en) Dried composition
DK3410854T3 (da) Mikrobicid sammensætning
ES1221034Y (es) Nueva composicion alimenticia
FI20185919A (fi) Biodieselkoostumus
ES1223299Y (es) Composicion de un alimento